(Q53223555)
English
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell
scientific article published in November 2006
Statements
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell (English)
Nizar M Tannir
Lorenzo Cohen
Xuemei Wang
Peter Thall
Paul F Mathew
Eric Jonasch
Arlene Siefker-Radtke
Lance C Pagliaro
Chaan S Ng
Christopher Logothetis
1 November 2006
107
9
2254-2261